Inventor · disambiguated record
Zhi Luo
Also filed as: LUO ZHI · Luo zhi-long
18 granted patents·3 pending applications·17 citations·filing 2009–2024
89Inventor score
Files withSHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD4ZHUHAI UNITED LABORATORIES CO LTD4CHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD3MEDSHINE DISCOVERY INC3SHANDONG DANHONG PHARMACEUTICAL CO LTD3
Top patents by PatentIndex Score
21 records- 0186US11932617B2Compound for use in retinal diseasesZHUHAI UNITED LABORATORIES CO LTD·Filed 2019·Granted Mar 19, 2024·3 cites·6 claims
- 0286US11001563B2SSAO inhibitorSHANDONG DANHONG PHARMACEUTICAL CO LTD·Filed 2019·Granted May 11, 2021·3 cites·19 claims
- 0385US10875888B2Steroid derivative FXR agonistCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2017·Granted Dec 29, 2020·3 cites·20 claims
- 0484US11505532B2SSAO inhibitorSHANDONG DANHONG PHARMACEUTICAL CO LTD·Filed 2021·Granted Nov 22, 2022·1 cites·9 claims
- 0583US11753377B2Crystal form of 2-methyl-2-propanol and amino-substituted aryl compoundZHUHAI UNITED LABORATORIES CO LTD·Filed 2021·Granted Sep 12, 2023·1 cites·14 claims
- 0681US2024287117A1Deuterated nucleoside compounds and use thereofMEDSHINE DISCOVERY INC·Filed 2024·Application pending·0 cites
- 0781US2024262837A1Deuterated nucleoside compounds and use thereofMEDSHINE DISCOVERY INC·Filed 2024·Application pending·0 cites
- 0878US10738076B2Lanosterol prodrug compound and preparation method therefor and use thereofZHONGSHAN OPHTHALMIC CENTER SUN YAT-SEN UNIV·Filed 2018·Granted Aug 11, 2020·3 cites·13 claims
- 0978US2024327446A1Deuterated nucleoside compounds and use thereofMEDSHINE DISCOVERY INC·Filed 2023·Application pending·0 cites
- 1070US10981860B2Caspase inhibitor and pharmaceutical composition, use and therapeutic method thereofCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2017·Granted Apr 20, 2021·1 cites·18 claims
- 1169US12479823B2Compound for use in retinal diseasesZHUHAI UNITED LABORATORIES CO LTD·Filed 2024·Granted Nov 25, 2025·0 cites·12 claims
- 1267US10912775B2Crystal form of orexin receptor antagonist compound, and preparation method and application thereofSHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD·Filed 2020·Granted Feb 9, 2021·0 cites·7 claims
- 1365US10874674B2Crystal form of orexin receptor antagonist compound, and preparation method and application thereofSHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD·Filed 2020·Granted Dec 29, 2020·0 cites·5 claims
- 1464US10898486B2Crystal form of orexin receptor antagonist compound, and preparation method and application thereofSHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD·Filed 2020·Granted Jan 26, 2021·0 cites·6 claims
- 1563US12077513B2Process route of compound of formula (IV), crystal form and preparation method thereforSHANDONG DANHONG PHARMACEUTICAL CO LTD·Filed 2019·Granted Sep 3, 2024·0 cites·16 claims
- 1663US11149055B2Crystal form of lanosterol prodrug compound and application thereofGUANGZHOU OCUSUN OPHTHALMIC BIOTECHNOLOGY CO LTD·Filed 2019·Granted Oct 19, 2021·0 cites·8 claims
- 1760US12473258B2Crystal form of pyridinylphenyl compound and preparation method thereforZHUHAI UNITED LABORATORIES CO LTD·Filed 2021·Granted Nov 18, 2025·0 cites·20 claims
- 1859US11667667B2Steroid derivative FXR agonistCHIA TAI TIANQING PHARMACEUTICAL GROUP CO LTD·Filed 2020·Granted Jun 6, 2023·0 cites·20 claims
- 1955US12329763B2Composition of lanosterol prodrug compound, preparation method therefor and use thereofGUANGZHOU OCUSUN OPHTHALMIC BIOTECHNOLOGY CO LTD·Filed 2020·Granted Jun 17, 2025·0 cites·18 claims
- 2053US10668066B2Crystal form of orexin receptor antagonist compound, and preparation method and application thereofSHANGHAI HAIYAN PHARMACEUTICAL TECH CO LTD·Filed 2016·Granted Jun 2, 2020·0 cites·7 claims
- 2148US8035794B2Double-layer liquid crystal lensUNITED RADIANT TECHNOLOGY CORP·Filed 2009·Granted Oct 11, 2011·2 cites·12 claims
Join the waitlist — get patent alerts
Get an alert when Zhi Luo files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →